Lee 2019 Immune Effector Cell-Associated Encephalopathy (ICE) points: orientation 0-4 (year, month, city, hospital), naming 0-3 (three objects), following commands 1, writing 1, attention 1 (count backward from 100 by tens); total 0-10. Caller-assigned; magent does not perform the exam. Not ASTCT ICANS grading. Deterministic published arithmetic with citation; not a medical device.

ICC 2022 systemic mastocytosis (Arber 2022). Met when major infiltrates (≥15 tryptase- and/or CD117-positive MCs in aggregates in BM or extracutaneous organ) alone, or ≥3 minors. Minors: >25% spindle or atypical immature morphology, KIT D816V or other activating KIT mutation, CD25/CD2/CD30, tryptase >20 ng/mL (not counted in SM-AMN). Not a diagnosis. Not Valent 2016 WHO SM. Not WHO 5th/Khoury. Not cutaneous mastocytosis only. magent does not read a biopsy or assay tryptase.

Lee 2019 ASTCT CRS Table 1 grade 0-4. Fever (>=38 C, not another cause) with both axes none is grade 1. fever_waived after antipyretic, tocilizumab, or steroids. Grade is the more severe of hypotension (none / no_vasopressors / one_vasopressor / multiple_vasopressors) vs hypoxia (none / low_flow / high_flow / positive_pressure). Organ toxicities do not influence grade. Not ICANS. magent does not measure temperature or start vasopressors.

Duval 2010 AML Table 5 (not ALL): PIF or CR1 >6 mo 0 / CR1 <6 mo 1; ECOG/SWOG cyto good/intermediate 0, poor 1; HLA sibling or well/partially matched unrelated 0, mismatched unrelated 1, related other 2; circulating blasts 1; KPS/Lansky <90 1; max 6. Groups 0, 1, 2, ≥3. Caller assigns categories; magent does not karyotype. Not a transplant listing.

NCI CTC v2.0 stomatitis/pharyngitis (Trotti 2000). none → 0; painless_or_mild_soreness → 1; painful_can_eat → 2; painful_cannot_eat → 3; parenteral_or_prophylactic_intubation → 4. magent does not examine the mucosa. Not radiation mucositis (nci-ctc-mucositis), CTCAE catalog, or WHO. Not a diagnosis or medical device.

ICC 2022 prefibrotic and overt PMF (Arber 2022). Diagnosed iff 3 majors and ≥1 minor. Majors: megakaryocyte morphology, not another myeloid neoplasm, JAK2/CALR/MPL or other clone or no reactive fibrosis. Minors: anemia not from comorbidity, WBC ≥11e9/L, splenomegaly, LDH above ULN; leukoerythroblastosis counts only in overt PMF. Not DIPSS, MIPSS70, WHO 5th, or post-PV/post-ET MF. magent does not read fibrosis grade or sequence drivers. Not a diagnosis or medical device.

Passamonti 2010 DIPSS for primary myelofibrosis: age >65 (1), WBC >25×10^9/L (1), hemoglobin <10 g/dL (2), peripheral-blood blasts ≥1% (1), constitutional symptoms (1); max 6. Low 0, intermediate_1 1–2, intermediate_2 3–4, high 5–6. Not DIPSS Plus or aaDIPSS. magent does not read a smear; constitutional symptoms are caller-assigned.

Greenberg 2012 IPSS-R for MDS: cytogenetics (very_good 0, good 1, intermediate 2, poor 3, very_poor 4; caller assigns the Schanz subgroup), BM blasts, hemoglobin g/dL, platelets, and ANC; max 10. very_low ≤1.5 through very_high >6. Deterministic published score with citation; not a diagnosis or transplant listing; not IPSS 1997 or IPSS-M. magent does not karyotype.

Tefferi 2018 GIPSS for primary myelofibrosis: karyotype (favorable 0, unfavorable 1, VHR 2; caller assigns the three-tier class), absence of type 1/like CALR 1, ASXL1 1, SRSF2 1, U2AF1Q157 1 (not S34); max 6. Low 0, intermediate_1 1, intermediate_2 2, high ≥3. Published median (5-year) survivals 26.4 y (94%), 8.0 y (73%), 4.2 y (40%), 2 y (14%). Not DIPSS or MIPSS70-plus. magent does not karyotype or sequence.

IMWG 2014 myeloma requiring therapy (Rajkumar 2014). Met when clonal BMPC ≥10% or biopsy-proven plasmacytoma plus ≥1 MDE: hypercalcemia, renal insufficiency, anemia, osteolytic lesion (CRAB), or BMPC ≥60%, involved:uninvolved FLC ratio ≥100 with involved FLC ≥100 mg/L, or >1 focal MRI lesion ≥5 mm (SLiM). Not a diagnosis. Not smouldering MM, MGUS, POEMS, or amyloid. Not Greipp ISS or R-ISS. magent does not assay calcium, creatinine, hemoglobin, or FLC, and does not read MRI.

Mekhail 2005 Motzer extension: KPS <80, LDH >1.5x ULN, hemoglobin <LLN, corrected calcium >10 mg/dL, prior radiotherapy, >=2 metastatic sites; 1 point each, max 6. Favorable 0-1, intermediate 2, poor >=3. Not Motzer 1999 0 / 1-2 / >=3. Not Motzer 2002 time-to-treatment. Mekhail dropped no-prior-nephrectomy. Deterministic published score with citation; not an RCC diagnosis or treatment recommendation; not IMDC. magent does not assign KPS, assay LDH, hemoglobin, or calcium, or image metastases.

Álvarez-Twose 2012 REMA: male +1, female −1; serum baseline tryptase <15 μg/L −1, 15–25 0, >25 +2; pruritus, hives or angioedema present −2, absent +1; syncope or presyncope +3. Range −4 to +7. Clonality likely iff score ≥2. Caller assigns sex, sBt, cutaneous signs, and syncope. Not a medical device, not a diagnosis of SM, not WHO SM criteria. magent does not assay tryptase.

Kumar 2016 IMWG measurable serum+urine M-protein response. First-match PD, sCR, CR, VGPR, PR, MR, or SD from caller-assigned flags. sCR is CR plus normal FLC ratio and no clonal BM cells by IHC. CR is negative serum and urine IFE, no plasmacytomas, and BMPC <5%. VGPR is electrophoresis-negative or ≥90% serum M-protein reduction with urine M-protein <100 mg/24 h. Not a diagnosis. Not MRD. Not FLC-only. magent does not assay labs.

Heng 2009 IMDC: KPS <80, diagnosis-to-treatment <1 year, hemoglobin <LLN, corrected calcium >ULN, neutrophils >ULN, platelets >ULN; 1 point each, max 6. Favorable 0, intermediate 1–2, poor ≥3. Deterministic published score with citation; not an RCC diagnosis or treatment recommendation. magent does not assign KPS or compare Hb, Ca, ANC, or platelets to institutional LLN/ULN.

4Ts score (Lo 2006) for heparin-induced thrombocytopenia pretest probability. Four caller-assigned integers 0-2 (thrombocytopenia, timing, thrombosis, other causes) using the published table; magent sums only (max 8). Bands 0-3 low, 4-5 intermediate, and 6-8 high pretest probability. Not a diagnosis of HIT, not the HEP score, and not an antibody result. magent does not grade platelet counts or day of onset.

Cuker 2010 HEP score: eight features with signed weights (range -16 to 19). Magnitude of platelet fall, typical- or rapid-onset timing, nadir, thrombosis (at most one), SQ heparin skin necrosis, IV-bolus systemic reaction, bleeding, and other causes (select all; no other cause +3). Cutoff 2 was 100% sensitive / 60% specific vs the expert panel. Not a HIT diagnosis or 4Ts score. magent does not assay SRA or ELISA.

Lansky 1987 Play-Performance Scale: caller-assigned integer 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 from parent-rated play over the past week (fully active; minor physical restriction; tires more quickly; restricted play; quieter activities; lying around, quiet play; mostly in bed; bedbound; often sleeping; no play; unresponsive). Grade 0 is scored. Returns score, max 100, and a stable label. Not a performance-status assignment, not Karnofsky, not ECOG; magent does not observe the child.

Oken 1982 ECOG performance status: caller-assigned integer 0-4 (fully active; restricted strenuous activity, ambulatory, light work; ambulatory, all self-care, unable to work, up >50% waking hours; limited self-care, bed/chair >50% waking hours; completely disabled, no self-care, totally bed/chair). Grade 5 (dead) is not scored. Returns score, max 4, and a stable label. Not a performance-status assignment and not Karnofsky; magent does not observe the patient.

Pardanani 2018 MAPS hybrid clinical-molecular (Figure 3): advanced SM 2 (ASM, SM-AHN, or MCL; ISM/SSM 0), age >60 1, platelets <150×10^9/L 1, ALP above UNL 1, ASXL1/RUNX1/NRAS 1; max 6. Low ≤2, intermediate-1 3, intermediate-2 4, high ≥5. Not WHO SM, not ICC SM, not clinical-only Figure 1. magent does not sequence, assay ALP, or count platelets.

Motzer 1999 MSKCC: KPS <80, LDH >1.5×ULN, hemoglobin <LLN, corrected calcium >10 mg/dL, no prior nephrectomy; 1 point each, max 5. Favorable 0, intermediate 1–2, poor ≥3. Deterministic published score with citation; not an RCC diagnosis or treatment recommendation; not IMDC; not Motzer 2002/2004. magent does not assign KPS or assay LDH, hemoglobin, or calcium.